Hengrui Medicine gets clinical trial nod, launches employee stock plan

Jiangsu Hengrui Medicine announced the approval for clinical trials of its drug cocktail comprising SHR-1826, Adberlimab, and Bevacizumab injections, aimed at treating solid tumors. The company's total R&D investment for SHR-1826 is approximately CNY 88.09 million, for Adberlimab is CNY 939.08 million, and for Bevacizumab is CNY 348.89 million. This marks a significant step towards potential market entry, pending successful clinical trials and regulatory approvals.

In a related development, the company’s shareholders approved the 2025 A-share Employee Stock Ownership Plan during a temporary shareholders' meeting held on September 16, 2025. This plan, with an approved allocation of up to 14 million shares (representing 0.21% of total share capital) at CNY 30.95 per share, aims to foster long-term growth by aligning employee and shareholder interests.

The stock plan's capital sources include legal compensation and self-raised funds from employees, with an expected participation of up to 1,316 employees. The shares will be acquired from the company's repurchased A-share stock account and will be unlocked in three phases over 36 months, contingent on company performance targets for innovative drug sales and IND/NDA approvals.